RxDoctor Payments Data

James Rester, MD

Internal Medicine · Garland, TXNPI 1013960426

Payments from drug & device makers

$2,050in general payments, 2019–2025

Across 123 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$686
  • Novo Nordisk$224
  • AbbVie$196
  • Amgen$158
  • Boehringer Ingelheim$147
  • Lilly USA, LLC$116
  • plus $523 from 13 others

What the payments were for

  • Food & beverage$2,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,050 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$73,247
Medicare patients
133
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab20$173,946
JardianceEmpagliflozin125$157,173
TrulicityDulaglutide69$105,129
OzempicSemaglutide49$67,794
FarxigaDapagliflozin Propanediol49$54,400
MounjaroTirzepatide37$36,666
XeljanzTofacitinib Citrate11$29,403
EliquisApixaban38$26,863
JanuviaSitagliptin Phosphate17$23,854
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$18,319
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$17,490
LinzessLinaclotide17$14,241
Repatha SureclickEvolocumab14$9,743
Praluent PenAlirocumab17$9,224
Breo ElliptaFluticasone/Vilanterol11$7,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$147$157,173125 claims
Lilly USA, LLCTrulicity, Mounjaro$116$141,795106 claims
Novo NordiskOzempic$224$67,79449 claims
PfizerXeljanz, Eliquis$48$56,26649 claims
AstraZenecaFarxiga$686$54,40049 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$100$31,68539 claims
MerckJanuvia$32$23,85417 claims
AbbVieLinzess, Synthroid$196$15,80639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →